22nd Century Group (XXII) Stock Analysis & Winston Score

22nd Century Group is a plant biotechnology company focused on tobacco and hemp. It uses genetic engineering to create tobacco plants with very low nicotine levels and hemp plants with specific cannabinoid profiles. The company is notable for receiving FDA authorization for its VLN brand, the first and only reduced-nicotine cigarettes allowed to be marketed in the United States. The company makes money by selling its VLN cigarettes in retail stores and through licensing its plant biotechnology to partners. It operates primarily in the United States and is a very small company by market cap. 22nd Century has a unique competitive position because of its FDA-authorized reduced-nicotine tobacco, which no other company currently offers. However, the company has consistently reported negative margins and significant operating losses, making its path to profitability and long-term viability a key risk for the business.